HarlanWeismanMD

PubMed

• PCORI at 3 years--progress, lessons, and plans.
  Selby JV Lipstein SH> ;N Engl J Med. 2014 Feb 13
• 118 citations
  Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention
  Keaven M. Anderson, Robert M. Califf, Gregg W. Stone, Franz-Josef Neumann, Gilles Montalescot, Dave P. Miller, James J. Ferguson, James T. Willerson, Harlan F. Weisman...> ;Journal of the American College of Cardiology. 2001 Jun 15
• 38 citations
  Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.
  Mary Ann Mascelli, Neal S. Kleiman, Stanley J. Marciniak, Lakshmi V. Damaraju, Harlan F. Weisman, Robert Jordan> ;American Heart Journal. 2000 Apr 1
• PLATELET GLYCOPROTEIN IIB/IIIA ANTAGONISTS IN ISCHEMIC CEREBROVASCULAR DISEASE
  Jacques R. Leclerc, Mary Ann Mascelli, Harlan F. Weisman> ;Coronary Artery Disease. 1999 Dec 1
• 2 citations
  An industry perspective on health economics studies
  Keaven M. Anderson, Mohan V. Bala, Harlan F. Weisman> ;American Heart Journal. 1999 May 1
• 109 citations
  Sustained Suppression of Ischemic Complications of Coronary Intervention by Platelet GP IIb/IIIa Blockade With Abciximab One-Year Outcome in the EPILOG Trial
  A. Michael Lincoff, James E. Tcheng, Robert M. Califf, Dean J. Kereiakes, Thomas A. Kelly, Gerald C. Timmis, Neal S. Kleiman, Joan E. Booth, Craig Balog, Catherine F. ...> ;Circulation. 1999 Apr 20
• 79 citations
  Diabetes Mellitus, Glycoprotein IIb/IIIa Blockade, and Heparin Evidence for a Complex Interaction in a Multicenter Trial
  Neal S. Kleiman, A.M. Lincoff, Dean J. Kereiakes, David P. Miller, Frank V. Aguirre, Keaven M. Anderson, Weisman Hf, Robert M. Califf, Eric J. Topol> ;Circulation. 1998 May 19
• 219 citations
  Pharmacodynamic Profile of Short-term Abciximab Treatment Demonstrates Prolonged Platelet Inhibition With Gradual Recovery From GP IIb/IIIa Receptor Blockade
  Mary Ann Mascelli, Ellen T. Lance, Lakshmi V. Damaraju, Carrie Wagner, Harlan F. Weisman, Robert E. Jordan> ;Circulation. 1998 May 5
• 58 citations
  Abciximab Therapy and Unplanned Coronary Stent Deployment Favorable Effects on Stent Use, Clinical Outcomes, and Bleeding Complications
  Dean J. Kereiakes, A.M. Lincoff, David P. Miller, James E. Tcheng, Catherine F. Cabot, Keaven M. Anderson, Weisman Hf, Robert M. Califf, Eric J. Topol> ;Circulation. 1998 Mar 10
• 49 citations
  Does Intracoronary Thrombus Influence the Outcome of High Risk Percutaneous Transluminal Coronary Angioplasty? Clinical and Angiographic Outcomes in a Large Multicente...
  M.Musa Khan, Stephen G. Ellis, Frank V. Aguirre, Harlan F. Weisman, Nancy M. Wildermann, Robert M. Califf, Eric J. Topol, Neal S. Kleiman> ;Journal of the American College of Cardiology. 1998 Jan 1
• 80 citations
  Rapid Assessment of Platelet Function With a Modified Whole-Blood Aggregometer in Percutaneous Transluminal Coronary Angioplasty Patients Receiving Anti-GP IIb/IIIa Th...
  Mary Ann Mascelli, Seth J. Worley, Nicholas J. Veriabo, Ellen T. Lance, Sabina Mack, Tom Schaible, Harlan F. Weisman, Robert Jordan> ;Circulation. 1997 Dec 2
• 196 citations
  Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator ...
  E.J. Topol, James J. Ferguson, Weisman Hf, James E. Tcheng, Stephen G. Ellis, Neal S. Kleiman, Russell J. Ivanhoe, Ann L. Wang, David P. Miller, Keaven M. Anderson, Ro...> ;JAMA. 1997 Aug 13
• 161 citations
  Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With U...
  A. Michael Lincoff, Robert M. Califf, Keaven M. Anderson, Harlan F. Weisman, Frank V. Aguirre, Neal S. Kleiman, Robert A. Harrington, Eric J. Topol> ;Journal of the American College of Cardiology. 1997 Jul 1
• 90 citations
  Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment Abciximab (c7E3 Fab) during per...
  A. Michael Lincoff, James E. Tcheng, Robert M. Califf, Theodore A. Bass, Jeffrey J. Popma, Paul S. Teirstein, Neal S. Kleiman, Larry J. Hattel, H. Vernon Anderson, Jam...> ;The American Journal of Cardiology. 1997 Feb 1
• 4 citations
  Clinical Benefit within Patient Subgroups Receiving c7E3 Fab (Abciximab) During Percutaneous Coronary Revascularization: Subgroup Analysis from the EPIC Trial.
  Frank V. Aguirre, Eric J. Topol, Keaven M. Anderson, Neal S. Kleiman, Harlan F. Weisman, Susan E. FitzPatrick, Robert M. Califf> ;The Journal of Invasive Cardiology. 1996 Dec 1
• 27 citations
  The Anti-GpIIb-IIIa Agents: Fundamental And Clinical Aspects
  Barry S. Coller, Keaven M. Anderson, Harlan F. Weisman> ;Haemostasis. 1996 Oct 1
• 49 citations
  Increased Risk of Non-Q Wave Myocardial Infarction After Directional Atherectomy Is Platelet Dependent: Evidence From the EPIC Trial
  Jeffrey Lefkovits, James C. Blankenship, Keaven M. Anderson, G L Stoner, J D Talley, Seth J. Worley, H F Weisman, Robert M. Califf, Eric J. Topol> ;Journal of the American College of Cardiology. 1996 Oct 1
• 304 citations
  Analysis of GPIIb/IIIa Receptor Number by Quantification of 7E3 Binding to Human Platelets
  Carrie Wagner, Mary Ann Mascelli, Donald S. Neblock, Harlan F. Weisman, Barry S. Coller, Robert E. Jordan> ;Blood. 1996 Aug 1
• 158 citations
  Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (Abciximab) on acute and six-month outcomes after percutaneous translumin...
  Jeffrey Lefkovits, Russell J. Ivanhoe, Robert M. Califf, Bruce A. Bergelson, Keaven M. Anderson, Gail L. Stoner, Harlan F. Weisman, Eric J. Topol> ;The American Journal of Cardiology. 1996 May 15
• 132 citations
  Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 ...
  Neal S. Kleiman, Albert E. Raizner, Robert E. Jordan, Ann L. Wang, Daniel Norton, Kenneth F. Mace, Alaknanda Joshi, Barry S. Coller, Harlan F. Weisman> ;Journal of the American College of Cardiology. 1995 Dec 1
• 64 citations
  The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant re...
  David M. Knight, Carrie Wagner, Robert Jordan, Mary Frances McAleer, Renato DeRita, David N. Fass, Barry S. Coller, Harlan F. Weisman, John Ghrayeb> ;Molecular Immunology. 1995 Nov 1
• 7 citations
  Blockade of the human platelet GPIIb/IIIa receptor by a murine monoclonal antibody Fab fragment (7E3): Potent dose-dependent inhibition of platelet function
  Shoumo Bhattacharya, Robert E. Jordan, Samuel J. Machin, Roxy Senior, Ian J. Mackie, Craig R. Smith, Thomas F. Schaible, Harlan F. Weisman, Avijit Lahiri> ;Cardiovascular Drugs and Therapy. 1995 Oct 1
• 88 citations
  New antiplatelet agents: platelet GPIIb/IIIa antagonists.
  Barry S. Coller, Keaven M. Anderson, Harlan F. Weisman> ;Thrombosis and Haemostasis. 1995 Jul 1
• 176 citations
  Bleeding Complications With the Chimeric Antibody to Platelet Glycoprotein IIb/IIIa Integrin in Patients Undergoing Percutaneous Coronary Intervention
  Frank V. Aguirre, Eric J. Topol, James J. Ferguson, Keaven M. Anderson, James C. Blankenship, Richard R. Heuser, Kristina N. Sigmon, Marc Taylor, Ronald S. Gottlieb, G...> ;Circulation. 1995 Jun 15
• 106 citations
  Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy ...
  David J. Moliterno, Robert M. Califf, Frank V. Aguirre, Keaven M. Anderson, Kristina N. Sigmon, Harlan F. Weisman, Eric J. Topol> ;The American Journal of Cardiology. 1995 Mar 15
• Join now to see all

Journal Articles

• Calcium-antagonist receptors in the atrial tissue of patients with hypertrophic cardiomyopathy.  
  Wagner JA, Sax FL, Weisman HF, Porterfield J, McIntosh C, Weisfeldt ML, Snyder SH, Epstein SE, N Engl J Med
• Laser backscatter studies of intracellular Ca2+ oscillations in the isolated hearts.  
  Stern MD, Weisman HF, Renlund DG, Gerstenblith G, Hano O, Lakatta EG, Am J Physiol
• Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow.  
  Ambrosio G, Weisman HF, Mannisi JA, Becker LC, Circulation
• Arterial hemodynamics in a rabbit model of atherosclerosis.  
  Zuckerman BD, Weisman HF, Yim FC, Am J Physiol
• Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia: Evidence for neutrophil-mediated reperfusion injury.  
  Litt MR, Jeremy RW, Weisman HF, Winkelstein JA, Becker LC, Circulation
• Economics and cost-effectiveness in evaluating the value of cardiovascular therapies: An industry perspective on health economics studies.  
  Anderson KM, Bala MV, Weisman HF, Am Heart J
• Paradoxical effects of exercise on the QT interval in patients with polymorphic ventricular tachycardia receiving type IA antiarrhythmic agents.  
  Kadish AH, Weisman HF, Veltri EP, Epstein AE, Slepian MJ, Levine JH, Circulation
• Diminished beta-adrenergic receptor responsiveness and cardiac dilation in hearts of myopathic Syrian hamsters (B10 53.58) are associated with a functional abnormality...  
  Feldman AM, Tena RG, Kessler PD, Weisman HF, Schulman SP, Blumenthal RS, Jackson DG, Van Dop C, Circulation
• Concept and Clinical Application of Platelet Glycoprotein IIb/IIIa Inhibition with Abciximab (c7E3 Fab; ReoPro) for the Prevention of Acute Ischemic Syndromes.  
  Anderson HV, Jordan RE, Weisman, HF, Clin Appl Thromb Hemost
• Differential effects of amiodarone and desethylamiodarone on calcium antagonist receptors.  
  Wagner JA, Weisman HF, Levine JH, Snowman AM, Snyder SH, J Cardiovasc Pharmacol
• The anti-GPIIb-IIIa agents: fundamental and clinical aspects.  
  Coller BS, Anderson KM, Weisman HF, Haemostasis
• Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis.  
  Weisman HF, Bartow T, Leppo MK, Marsh HC, Jr., Carson GR, Concino MF, Boyle MP, Roux KH, Weisfeldt ML, Fearon DT, Science
• ReoPro Clinical Development: Future Directions and Therapeutic Approaches.  
  Weisman HF, J Invas Cardiol
• Plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography.  
  Herrington DM, Gordon GB, Achuff SC, Trejo JF, Weisman HF, Kwiterovich PO Jr., Pearson TA, J Am Coll Cardiol
• Recombinant soluble CR1 suppresses complement activation, inflammation and necrosis associated with reperfusion of ischemic myocardium.  
  Weisman HF, Bartow T, Leppo MK, Boyle MP, Marsh HC, Carson GR, Roux KH, Weisfeldt ML, Fearon DT, Trans Assoc Am Physicians
• Comparison of indium 111 antimyosin antibody and technetium 99m pyrophosphate localization in reperfused and nonreperfused myocardial infarction.  
  Takeda K, LaFrance ND, Weisman HF, Wagner HN Jr., Becker LC, J Am Coll Cardiol
• New antiplatelet agents: Platelet GPIIb/IIIa antagonists.  
  Coller BS, Anderson K, Weisman HF, Thromb Haemost
• Anti-platelet monoclonal antibodies for the prevention of arterial thrombosis: Experience with ReoPro, a monoclonal antibody directed against the platelet GPIIb/IIIa r...  
  Weisman HF, Schaible TF, Jordan RE, Cabot CF, Anderson KM, Biochem Soc Trans
• Intravenous administration of monoclonal antibody to the platelet GPIIb/IIIa receptor to treat abrupt closure during coronary angioplasty.  
  Anderson HV, Revana M, Rosales O, Brannigan L, Stuart Y, Weisman H, Willerson J, Amer J Cardiol
• Cardiovascular applications: Current status of immunoscintigraphy in the detection of myocardial necrosis using antimyosin (R11D10) and deep venous thrombosis using an...  
  Manspeaker HP, Weisman HF, Schaible TF, Semin Nucl Med
• The role of calcium channel abnormalities in syrian hamster cardiomyopathy.  
  Weisman HF, Clin Immunol Immunopathol
• Imaging of vascular injury with 99m tc-labeled monoclonal antiplatelet antibody S12: Preliminary experience in human percutaneous transluminal angioplasty.  
  Miller DD, Rivera FJ, Garcia OJ, Palmaz JC, Berger HJ, Weisman HF, Circulation
• Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents.  
  Coller BS, Scudder LE, Beer J, Gold HK, Folts JD, Cavagnaro J, Jordan R, Wagner C, Iuliucci J, Knight D, Ghrayeb J, Smith C, Weisman HF, Berger H, Annals New York Academy of Sciences
• Prospects for the use of antagonists to the platelet glycoprotein IIb/IIIa receptor to prevent post-angioplasty restenosis and thrombosis.  
  Ellis SG, Bates ER, Schaible T, Weisman HF, Pitt B, Topol EJ, J Am Coll Cardiol
• A method to reconstruct myocardial sarcomere lengths and orientations at transmural sites in beating canine hearts.  
  Rodriguez EK, Hunter WC, Royce MJ, Leppo MK, Douglas AS, Weisman HF, Am J Physiol
• Join now to see all

Books/Book Chapters

• How to Write and Publish in the Medical Sciences. 
  Weisman HFEditors: Edward J. Huth.ISI Press, Philadelphia
• Catheter Ablation of Cardiac Arrhythmias. 
  Chapter: Cellular electrophysiology of electrical discharges 
  Page 37 - 50Levine JH, Spear JF, Kadish AH, Weisman HF, Merillat JC, Moore ENEditors: Melvin M. Scheinman.Martinus Nijhoff Publishing, Boston
• Heart Disease. A textbook of cardiovascular medicine. 
  Chapter: Inhibitors of platelets agreggation: GPIIb/IIIa antagonists 
  Page 1 - 10Coller BS, Anderson KA, Weisman HFEditors: Eugene Braunwald.W.B. Sanders Company
• Adhesion Receptors as Therapeutic Targets. 
  Chapter: Preclinical development of c7E3 Fab; a mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GPIIb/IIIa receptors with observations 
  Page 281 - 305Jordan RE, Wagner CL, Mascelli MA, Treacy G, Nedelman MA, Woody JN, Weisman HF, Coller BSCRC Press Inc
• Therapeutic Drugs. 
  Chapter: Abciximab Chapter 
  Simoons M, Weisman HF, Jordan RColin Dollery
• Coronary Artery Disease. 
  Chapter: Platelet glycoprotein IIb/IIIa antagonists in ischemic cerebrovascular disease 
  Page 575 - 579LeClerc J, Mascelli MA, Weisman HF
• New Therapeutic Agents in Thrombosis and Thrombolysis. 
  Chapter: The pharmacology and clinical development of abciximab (c7E3 Fab): A monoclonal antibody inhibitor of GPIIb/IIIa and ?v?3 
  Jordan RE, Mascelli MA, Nakada M, Weisman HFMarcel Dekker, Inc, New York
• Molecular Basis of Oxidative Damage by Leukocytes. 
  Chapter: Electron paramagnetic resonance measurements of free radical generation in isolated cells and whole tissues 
  Page 181 - 201Zweier JL, Kuppusamy P, Shandelya SML, Thompson-Gorman S, Weisman HF, Fearon DT, Weisfeldt MLCRC Press Inc
• Value in Health Care: Accounting for Cost, Quality, Safety, Outcomes, and Innovation. 
  Chapter: Stakeholder Perspectives on Value: Perspectives from Manufacturers 
  Weisman, Harlan FEditors: Yong PL, Olsen LA, McGinnis JM.National Academies Press, Washington
• The 2009 Pfeiffer Annual Leadership Development. 
  Chapter: Convergence and Innovation 
  Page 179 - 187Weisman, HEditors: David Dotlich, Peter Cairo, Stephen Rhinesmith, and Ron Meeks.Pfeiffer Publishing, San Francisco
• The Learning Healthcare System: Workshop Summary, Institute of Medicine of the National Aademies. 
  Chapter: Broader Post-Marketing Surveillance for Insights on Risk and Effectiveness 
  Weisman, H., Farup, C., Thomas, A., Juhn, P., Buto, KThe National Academies Press, Washington
• Novel Therapeutic Proteins: Selected Case Studies. 
  Chapter: The Evolution of ReoPro® Clinical Development 
  Page 323 - 346Farrell, CF, Barnathan, ES, Weisman HFWiley-VCH
• Handbook of Experimental Pharmacology. 
  Chapter: Current Antiplatelet Therapy 
  Jakubowski, J., Jordan, R.E., Weisman, H.FSpringer-Verlag
• Join now to see all